Last $2.64 USD
Change Today +0.03 / 1.15%
Volume 34.1K
As of 9:37 AM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

achillion pharmaceuticals (ACHN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/1/13 - $8.49
52 Week Low
10/31/13 - $2.26
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

achillion pharmaceuticals (ACHN) Related Businessweek News

No Related Businessweek News Found

achillion pharmaceuticals (ACHN) Details

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and resistant bacterial infections. The company’s drug candidates for treating chronic HCV infection comprise Sovaprevir, a NS3/4A protease inhibitor, which has completed a Phase IIa clinical trial; ACH-3102, a NS5A inhibitor that is in Phase IIa clinical trial; ACH-3422, a NS5B nucleotide polymerase inhibitor, which has completed preclinical studies; and ACH-2684, a NS3/4A protease inhibitor that has completed Phase Ia and Ib clinical trials. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

61 Employees
Last Reported Date: 03/7/14
Founded in 1998

achillion pharmaceuticals (ACHN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $376.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $300.8K
Chief Compliance Officer and Executive Vice P...
Total Annual Compensation: $321.9K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $304.2K
Compensation as of Fiscal Year 2012.

achillion pharmaceuticals (ACHN) Key Developments

Achillion Announces Management Changes

Achillion Pharmaceuticals, Inc. announced that Mary Kay Fenton has been promoted to Executive Vice President and Chief Financial Officer and that Joseph Truitt has been promoted to Executive Vice President and Chief Commercial Officer.

Achillion Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2013; Provides Earnings Guidance for 2014

Achillion Pharmaceuticals, Inc. announced unaudited earnings results for the fourth quarter and year ended December 31, 2013. For the three months ended December 31, 2013, the Company reported a net loss of $13.4 million or $0.14 per basic and diluted share, compared to a net loss of $11.2 million or $0.14 per basic and diluted share in the three months ended December 31, 2012. Loss from operations was $13,494,000 against $11,254,000 a year ago. For the full year ended December 31, 2013, the company's net loss was $59.0 million, or $0.63 per share, compared to a net loss of $47.1 million for the year ended December 31, 2012, or $0.64 per share. Loss from operations was $59,477,000 against $47,293,000 a year ago. The company expects that net cash used in operating activities in 2014 will be approximately $60 to $65 million based on current operating plans, anticipated timelines and the estimated cost of clinical trials and product development programs. The net loss per share is anticipated to approximate $0.70 per share.

Achillion Mulls Acquisitions

Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN) has filed a shelf registration in the amount of $150 million. The proceeds will be used for general corporate purposes may include research and development expenditures, the acquisition of companies or businesses, repayment and refinancing of debt, working capital and capital expenditures.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACHN:US $2.63 USD +0.02

ACHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACHN.
View Industry Companies

Industry Analysis


Industry Average

Valuation ACHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACHILLION PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at